Polen Capital Management LLC Buys 5,173 Shares of Repligen Co. (NASDAQ:RGEN)

Polen Capital Management LLC lifted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 14.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,556 shares of the biotechnology company’s stock after purchasing an additional 5,173 shares during the quarter. Polen Capital Management LLC owned 0.07% of Repligen worth $5,838,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Champlain Investment Partners LLC raised its stake in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares during the period. Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after purchasing an additional 6,872 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after purchasing an additional 36,773 shares during the period. DF Dent & Co. Inc. increased its stake in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in Repligen by 2.5% in the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock worth $83,693,000 after acquiring an additional 14,398 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

RGEN has been the topic of a number of research analyst reports. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Trading Up 5.7 %

RGEN opened at $150.62 on Monday. The stock has a market cap of $8.44 billion, a PE ratio of -295.33, a PEG ratio of 4.54 and a beta of 0.95. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average of $157.19 and a 200-day moving average of $148.52. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $200.23.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Equities research analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.